Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2019

View Archived Issues

In vivo research suggests E-cadherin drives metastasis

Bug likes bleach

Wharton's jelly-derived mesenchymal stem cells evaluated in chronic ischemic heart failure

GT Biopharma initiates enrollment in first-in-human study of GTB-3550

Navitor presents data from phase I program of NV-5138

Dahl-S model of hypertension associates higher cerebral blood flow with lower anxiety level

LCGA-17 peptide shows anxiolytic and antidepressant activity in zebrafish

BoNTANA Therapies describes nucleic acids encoding botulinum neurotoxins

CD47 single-domain antibodies patented by Shanghai Novamab Biopharmaceuticals

Adamed Pharma discovers dual 5-HT2A and 5-HT6 receptor antagonists

Fraunhofer-Gesellschaft identifies inhibitors of bacterial glutaminyl cyclases

New protein-arginine deiminase type-4 inhibitors synthesized at Nanjing TransThera Biosciences

Pharvaris announces financing to advance clinical development of HAE oral therapy

AgeneBio receives support for GABA-A alpha5 PAM program

Spinal SGK1 is involved in the development of morphine tolerance through NF-kB p65/NMDAR signaling

S100A9/TLR4 axis can be a target for the management of insulin deficiency

Red blood cell transfusions in anemic murine neonates cause necrotizing enterocolitis

CADPA multi-biomarker score identifies hidden risk of acute coronary syndromes

Phase I results of nivolumab, ipilimumab and nintedanib combination in advanced NSCLC presented

Study shows just how far precision target ID has yet to go

Phase III trial of Toca-511/Toca-FC in recurrent high-grade glioma misses primary endpoint

Ovid begins pivotal trial of OV-101 for Angelman syndrome

FDA approves Ibsrela for irritable bowel syndrome with constipation

ALK inhibitor PLB-1003 shows promising results in a phase Ia trial

ADC Therapeutics studies ADCT-301 for relapsed or refractory Hodgkin's lymphoma in phase II

Phase III study of CC-486 as maintenance therapy in AML meets primary and key secondary endpoints

Ritter's phase III trial of RP-G28 for lactose intolerance misses primary endpoint

Noxxon initiates phase I/II trial of NOX-A12 with radiotherapy for newly diagnosed brain cancer

Orion Biotechnology obtains Polish clearance to begin phase I study of microbicide gel

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...